ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Khanna, Anchit ^a,b   Okkeri, Juha ^c   Bilgen, Turker ^a,c,d   Tiirikka, Timo ^a   Vihinen, Mauno ^a   Visakorpi, Tapio ^a   Westermarck, Jukka ^a,c  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CANCEROUS INHIBITOR OF PHOSPHOPROTEIN PHOSPHATASE 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; ONCOPROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG; DNA; ETS1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; STEROID HORMONE 7 ALPHA HYDROXYLASE; STEROID HORMONE 7-ALPHA-HYDROXYLASE; STEROID MONOOXYGENASE; UNSPECIFIC MONOOXYGENASE;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CANCER GROWTH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC CONSERVATION; GENETIC REGULATION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; DRUG ANTAGONISM; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE;

ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; CELL LINE, TUMOR; DNA; DNA METHYLATION; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEIN C-ETS-1; STEROID HYDROXYLASES;

EID: 79952916409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017979     Document Type: Article

References (39)

1. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
2. Zhao JJ, Roberts TM, Hahn WC, (2004) Functional genetics and experimental models of human cancer. Trends Mol Med 10: 344-350.
3. Ciardiello F, Tortora G, (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
4. Knight ZA, Lin H, Shokat KM, (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10: 130-137.
5. Montagut C, Settleman J, (2009) Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283: 125-134.
6. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
7. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
8. Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, et al. (2009) Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 8: 2526-2536.
9. Dent P, Curiel DT, Fisher PB, Grant S, (2009) Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat 12: 65-73.
10. Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, et al. (2006) The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 207: 420-427.
11. Sharrocks AD, (2001) The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2: 827-837.
12. Yang BS, Hauser CA, Henkel G, Colman MS, Van Beveren C, et al. (1996) Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol 16: 538-547.
13. Seth A, Watson DK, (2005) ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462-2478.
14. Watson DK, McWilliams-Smith MJ, Nunn MF, Duesberg PH, O'Brien SJ, et al. (1985) The ets sequence from the transforming gene of avian erythroblastosis virus, E26, has unique domains on human chromosomes 11 and 21: both loci are transcriptionally active. Proc Natl Acad Sci U S A 82: 7294-7298.
15. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, et al. (2010) Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29: 2147-2160.
16. Seth A, Catzavelos C, Vary C, Ascione R, (2001) ETS transcription factors and targets in tumour invasion, angiogenesis and bone metastasis. Expert Opin Ther Targets 5: 87-107.
17. Seth A, Papas TS, (1990) The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated. Oncogene 5: 1761-1767.
18. Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F, et al. (2005) Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene 24: 5384-5388.
19. Holterman CE, Franovic A, Payette J, Lee S, (2010) ETS-1 oncogenic activity mediated by transforming growth factor alpha. Cancer Res 70: 730-740.
20. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, et al. (2007) CIP2A inhibits PP2A in human malignancies. Cell 130: 51-62.
21. Junttila MR, Westermarck J, (2008) Mechanisms of MYC stabilization in human malignancies. Cell Cycle 7: 592-596.
22. Come C, Laine A, Chanrion M, Edgren H, Mattila E, et al. (2009) CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15: 5092-5100.
23. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, et al. (2010) CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis. Ann Surg Oncol.
24. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, et al. (2009) MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 101: 793-805.
25. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, et al. (2008) CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 14: 3722-3728.
26. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, et al. (2010) CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene.
27. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, et al. (1998) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58: 5321-5325.
28. Johnson AC, Murphy BA, Matelis CM, Rubinstein Y, Piebenga EC, et al. (2000) Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression. Mol Med 6: 17-27.
29. van Dam H, Duyndam M, Rottier R, Bosch A, de Vries-Smits L, et al. (1993) Heterodimer formation of cJun and ATF-2 is responsible for induction of c-jun by the 243 amino acid adenovirus E1A protein. EMBO J 12: 479-487.
30. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, et al. (2007) New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 8: 871-878.
31. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, et al. (2008) An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112: 4193-4201.
32. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, et al. (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113: 3088-3091.
33. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873.
34. Soo Hoo L, Zhang JY, Chan EK, (2002) Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 21: 5006-5015.
35. Hollenhorst PC, Jones DA, Graves BJ, (2004) Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 32: 5693-5702.
36. Hollenhorst PC, Chandler KJ, Poulsen RL, Johnson WE, Speck NA, et al. (2009) DNA specificity determinants associate with distinct transcription factor functions. PLoS Genet 5: e1000778.
37. Dittmer J, (2003) The biology of the Ets1 proto-oncogene. Mol Cancer 2: 29.
38. Wang J, Li W, Li L, Yu X, Jia J, et al. (2011) CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol.
39. Oberley MJ, Farnham PJ, (2003) Probing chromatin immunoprecipitates with CpG-island microarrays to identify genomic sites occupied by DNA-binding proteins. Methods Enzymol 371: 577-596.